Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Recruiting
130 enrolled
PROVIDENCE
Recruiting
800 enrolled
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
Recruiting
800 enrolled
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Completed
1,083 enrolled 29 charts
RESONATE
Completed
335 enrolled
TavieSkin
Completed
400 enrolled
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Completed
779 enrolled 9 charts
EchoTip AcuCore Post-Market Clinical Study
Completed
183 enrolled
GS_ZKM
Recruiting
200 enrolled
START
Terminated
10 enrolled
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Completed
9,122 enrolled
INGA
Active not recruiting
600 enrolled
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Completed
242 enrolled
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
Completed
24 enrolled
FINN
Active not recruiting
825 enrolled
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
Completed
22,517 enrolled
Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow
Completed
8 enrolled
OSPREY
Recruiting
500 enrolled
StivargaPMS
Completed
316 enrolled
HOMING
Completed
421 enrolled
Treat ER+ight
Completed
440 enrolled
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Terminated
22 enrolled
Poseidon
Completed
151 enrolled
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study
Completed
408 enrolled
VOLUME-PRO
Completed
509 enrolled
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
Completed
304 enrolled
Post-Marketing Surveillance of Lenvima in Korean Patients
Completed
132 enrolled
NEPTUN
Completed
408 enrolled
CHAPLIN
Completed
154 enrolled
Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.
Unknown
80 enrolled
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
Terminated
1,583 enrolled
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Terminated
2 enrolled
PIONEER
Unknown
1,000 enrolled
PROXie
Completed
253 enrolled
REVEAL
Completed
141 enrolled
COSMiC
Completed
194 enrolled
RENACALL
Completed
70 enrolled 32 charts
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Completed
125 enrolled
BioPATH
Completed
158 enrolled
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
Completed
1,000 enrolled
CERAM
Completed
132 enrolled 11 charts
FMI Registry
Completed
510 enrolled
Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer
Completed
80 enrolled
GeneSearch Breast Lymph Node (BLN) Assay Timing Study
Terminated
233 enrolled
GeneSearchâ„¢ Breast Lymph Node (BLN) Assay Post Approval Study
Terminated
461 enrolled
TOP
Completed
761 enrolled 17 charts
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Completed
730 enrolled
Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients
Completed
1,524 enrolled
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Terminated
146 enrolled
RESECT
Completed
60 enrolled